Nurse Practitioner Program year 2025 Reported 2024–2025 Source: CMS Open Payments, 2026 publication

Lisa Wiley

Nephrology Kansas City, MO Nurse Practitioner

NPI 1346005337 CMS profile 11625145

2340 E Meyer Blvd, Bldg 2 Suite 480, Kansas City, MO 64132

Open in the dashboard

General payments

$1,178

68 records reported · program years 2024–2025

Research payments

$0

Paid to them · None reported · program years 2024–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lisa Wiley of Kansas City, MO is reported in the CMS Open Payments database as having received $1,178 across 68 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 52nd percentile of Nephrology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $704 44
2024 General $474 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lisa Wiley
  • Nephrology median
  • Middle half of Nephrology
  • National median

In program year 2025, general payments to Lisa Wiley were reported at $704. Among 8,186 Nephrology profiles paid that year, the median was $310 and the middle half received between $104 and $880.

Show as a table
Year Lisa Wiley Nephrology median Middle half National median
2019 $0 $236 $90–$588 $163
2020 $0 $135 $46–$364 $114
2021 $0 $202 $67–$551 $132
2022 $0 $242 $77–$695 $149
2023 $0 $254 $84–$766 $160
2024 $474 $300 $99–$852 $164
2025 $704 $310 $104–$880 $169

Breakdown

Who paid General payments · program years 2024–2025
  1. Retrophin, Inc. $422 33 payments
  2. Calliditas Therapeutics US Inc. $152 6 payments
  3. Akebia Therapeutics Inc $95 6 payments
  4. Novartis Pharmaceuticals Corporation $91 3 payments
  5. ANI Pharmaceuticals, Inc. $67 3 payments
  6. Amgen Inc. $48 2 payments
  7. GlaxoSmithKline, LLC. $42 2 payments
  8. Novo Nordisk Inc $40 2 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $40 2 payments
  10. Scpharmaceuticals Inc. $35 2 payments
  11. Other $146 7 payments

Every payment, record by record

What the payments were for General payments · program years 2024–2025
  1. Food and Beverage $1,178 68 payments
Products named General payments · program years 2024–2025
  1. TARPEYO Nephrology $110 4 payments
  2. Vafseo $95 6 payments
  3. Fabhalta $91 3 payments
  4. PURIFIED CORTROPHIN GEL $67 3 payments
  5. Vanrafia $65 2 payments
  6. TAVNEOS $48 2 payments
  7. Auryxia $48 3 payments
  8. BENLYSTA $42 2 payments
  9. TARPEYO Nephrology $41 2 payments
  10. Ozempic $40 2 payments
  11. Other $241 12 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

89

Median for Nurse Practitioner: 389

Drug cost

$1,121

Median for Nurse Practitioner: $21,885

Branded share of claims

15.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nifedipine Er Nifedipine Brand 14 $535
Potassium Chloride Generic 26 $303
Torsemide Generic 14 $113
Carvedilol Generic 19 $90
Losartan Potassium Generic 16 $81

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 2 billing codes

Paid by Medicare

$12,993

Medicare's payments for the services billed

Medicare patients

132

Average age 76

Services billed

173

77 women, 55 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 75%
Diabetes 61%
Arthritis 50%
Ischemic heart disease 49%
Heart failure 39%
Depression 32%
Atrial fibrillation 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
PURIFIED CORTROPHIN GEL
  • ANI Pharmaceuticals, Inc. $45
$45 — —
TARPEYO
  • CALLIDITAS THERAPEUTICS US INC. $41
$41 — —
Ozempic
  • Novo Nordisk Inc $40
$40 — —
Vafseo
  • AKEBIA THERAPEUTICS INC $37
$37 — —
Fabhalta
  • Novartis Pharmaceuticals Corporation $26
$26 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

68 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nephrology in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record